https://assets.capyfin.com/instruments/678fdc13234e27009c5d5b25.png avatar
Masimo
đŸ‡ºđŸ‡¸ NASDAQ:MASI
View Company
OverviewEarningsDividends
•
Mar 30, 2024

Masimo Q1 2024 Earnings Report

Reported first quarter 2024 financial results.

Key Takeaways

Masimo's consolidated revenue was $492.8 million, with healthcare revenue at $339.6 million and non-healthcare revenue at $153.2 million. The company reported a GAAP net income per diluted share of $0.35 and a non-GAAP net income per diluted share of $0.77.

Consolidated revenue reached $492.8 million.

Healthcare revenue amounted to $339.6 million.

Non-healthcare revenue totaled $153.2 million.

GAAP net income per diluted share was $0.35, while non-GAAP net income per diluted share was $0.77.

Total Revenue
$493M
Previous year: $565M
-12.8%
EPS
$0.66
Previous year: $0.87
-24.1%
Gross Profit
$242M
Previous year: $285M
-15.1%
Cash and Equivalents
$158M
Previous year: $174M
-9.5%
Free Cash Flow
$37.6M
Previous year: -$8.1M
-564.2%
Total Assets
$2.96B
Previous year: $3.12B
-5.1%

Masimo

Masimo

Forward Guidance

Masimo provided estimates for its second quarter 2024 and updated full-year 2024 guidance.

Positive Outlook

  • Consolidated revenue is expected to be between $480 million and $510 million for Q2 2024 and between $2,055 million and $2,165 million for the full year 2024.
  • Healthcare revenue is projected to be between $330 million and $340 million for Q2 2024 and between $1,355 million and $1,385 million for the full year 2024.
  • Non-healthcare revenue is anticipated to be between $150 million and $170 million for Q2 2024 and between $700 million and $780 million for the full year 2024.
  • Consolidated operating income is estimated to be between $33 million and $38 million (GAAP) or $67 million and $72 million (Non-GAAP) for Q2 2024.
  • Consolidated earnings per diluted share are expected to be between $0.26 and $0.33 (GAAP) or $0.73 and $0.79 (Non-GAAP) for Q2 2024.

Challenges Ahead

  • The estimates are based on current expectations and are subject to uncertainties and factors that could cause actual results to differ materially.
  • Risks include dependence on Masimo SET® and Masimo rainbow SETâ„¢ products, competition, and failure to develop innovative products.
  • The guidance is subject to the company's ability to manage cost structure and the pace of recovery in inpatient volumes.
  • Potential uncertainty during the pendency of any such potential separation that could affect Masimo’s financial performance
  • Negative effects of the announcement or pendency of any such potential separation on the market price of Masimo’s securities and/or on the financial performance of Masimo

Company Overview

Full financial data and analysis

View Masimo